
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5879704/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Invasive Right Ventricular Pressure-Volume Analysis: Basic Principles, Clinical Applications, and Practical Recommendations. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009101.	1.6	39
2	Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations. Therapeutics and Clinical Risk Management, 2022, Volume 18, 315-322.	0.9	13
3	Artificial Intelligence and Mechanical Circulatory Support. Heart Failure Clinics, 2022, 18, 301-309.	1.0	2
4	Center Variability in Patient Outcomes Following HeartMate 3 Implantation: An Analysis of the MOMENTUM 3 Trial. Journal of Cardiac Failure, 2022, 28, 1158-1168.	0.7	12
5	A New Dawn for Transvalvular Pumps for Ventricular Unloading as a Bridge to Heart Transplantation. ASAIO Journal, 2022, 68, 760-762.	0.9	0
6	ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. Journal of Heart and Lung Transplantation, 2022, 41, 1135-1194.	0.3	17
7	Criteria for Defining Stages of Cardiogenic Shock Severity. Journal of the American College of Cardiology, 2022, 80, 185-198.	1.2	74
8	Delineating Pathways to Death by Multisystem Organ Failure in Patients With a Left Ventricular Assist Device. Annals of Thoracic Surgery, 2021, 111, 881-888.	0.7	8
9	Impact of cytomegalovirus infection on gene expression profile in heart transplant recipients. Journal of Heart and Lung Transplantation, 2021, 40, 101-107.	0.3	9
10	Elevated Pulmonary Pressure Noted on Echocardiogram: A Simplified Approach to Next Steps. Journal of the American Heart Association, 2021, 10, e017684.	1.6	10
11	Outcomes of patients hospitalized for acute pulmonary embolism by obstructive sleep apnea status. Pulmonary Circulation, 2021, 11, 1-9.	0.8	6
12	Right Ventricular Pressure-Volume Analysis During a Left Ventricular Assist Device Speed Optimization Study. Circulation: Heart Failure, 2021, 14, e008014.	1.6	2
13	Clinical Outcomes Associated With Acute Mechanical Circulatory Support Utilization in Heart Failure Related Cardiogenic Shock. Circulation: Heart Failure, 2021, 14, e007924.	1.6	48
14	Phenotyping Cardiogenic Shock. Journal of the American Heart Association, 2021, 10, e020085.	1.6	74
15	ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part II: Cardiac, surgical, perioperative, operative, and post-operative challenges and management statements. Journal of Heart and Lung Transplantation, 2021, 40, 1267-1278.	0.3	1
16	Defining Optimal Outcomes in Patients with Left Ventricular Assist Devices. ASAIO Journal, 2021, 67, 397-404.	0.9	8
17	Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH. Pulmonary Circulation, 2020, 10, 1-12.	0.8	6
18	Complete Hemodynamic Profiling With Pulmonary Artery Catheters in Cardiogenic Shock Is Associated With Lower In-Hospital Mortality. JACC: Heart Failure, 2020, 8, 903-913.	1.9	163

#	Article	IF	CITATIONS
19	Risk stratification in pulmonary arterial hypertension using Bayesian analysis. European Respiratory Journal, 2020, 56, 2000008.	3.1	38
20	Bionic women and men ―Part 2: Arterial stiffness in heart failure patients implanted with left ventricular assist devices. Experimental Physiology, 2020, 105, 755-758.	0.9	3
21	Biomarkers in pulmonary arterial hypertension: Moving closer toward precision medicine?. Journal of Heart and Lung Transplantation, 2020, 39, 287-288.	0.3	5
22	Bionic women and men ―Part 1: Cardiovascular lessons from heart failure patients implanted with left ventricular assist devices. Experimental Physiology, 2020, 105, 749-754.	0.9	5
23	National trends and inpatient outcomes of pulmonary arterial hypertension related hospitalizations – Analysis of the National Inpatient Sample Database. International Journal of Cardiology, 2020, 319, 131-138.	0.8	7
24	Bionic women and men ―Part 4: Cardiovascular, cerebrovascular and exercise responses among patients supported with left ventricular assist devices. Experimental Physiology, 2020, 105, 763-766.	0.9	7
25	Bionic women and men ―Part 3: Right ventricular dysfunction in patients implanted with left ventricular assist devices. Experimental Physiology, 2020, 105, 759-762.	0.9	6
26	Data on clinical and economic burden associated with pulmonary arterial hypertension related hospitalizations in the United States. Data in Brief, 2020, 32, 106303.	0.5	2
27	Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor. Chest, 2019, 156, 1176-1186.	0.4	32
28	Factors Affecting Health Care Engagement of Patients With End-Stage Heart Failure: An Exploratory Survey Study. MDM Policy and Practice, 2019, 4, 238146831986551.	0.5	0
29	Sex-Based Differences in Left Ventricular Assist Device Utilization. Circulation: Heart Failure, 2019, 12, e006082.	1.6	44
30	The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension. Current Hypertension Reports, 2019, 21, 45.	1.5	20
31	Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: A prospective multicenter study. American Journal of Transplantation, 2019, 19, 2889-2899.	2.6	138
32	Transition From Oral Treprostinil to Selexipag in a Patient With Pulmonary Arterial Hypertension. Annals of Pharmacotherapy, 2019, 53, 764-765.	0.9	3
33	Risk Assessment in Patients with a Left Ventricular Assist Device Across INTERMACS Profiles Using Bayesian Analysis. ASAIO Journal, 2019, 65, 436-441.	0.9	10
34	Multicenter Experience of Concomitant Use ofÂLeft Ventricular Assist Devices and Subcutaneous Implantable Cardioverter-Defibrillators. JACC: Clinical Electrophysiology, 2018, 4, 1261-1262.	1.3	13
35	Retrospective Evaluation of Bayesian Risk Models of LVAD Mortality at a Single Implant Center. Frontiers in Medicine, 2018, 5, 277.	1.2	1
36	A Bayesian Model to Predict Survival After Left Ventricular Assist Device Implantation. JACC: Heart Failure, 2018, 6, 771-779.	1.9	45

#	Article	IF	CITATIONS
37	Challenges and Future Directions in Left Ventricular Assist Device Therapy. Critical Care Clinics, 2018, 34, 479-492.	1.0	11
38	Risk Assessment in Pulmonary Arterial Hypertension Patients: The Long and Short of it. Advances in Pulmonary Hypertension, 2018, 16, 125-135.	0.1	12
39	Significance of Residual Mitral Regurgitation After Continuous Flow LeftÂVentricular Assist Device Implantation. JACC: Heart Failure, 2017, 5, 81-88.	1.9	68
40	Prediction model for cardiac allograft vasculopathy: Comparison of three multivariable methods. Clinical Transplantation, 2017, 31, e12925.	0.8	16
41	Low Accuracy of the HeartMate Risk Score for Predicting Mortality Using the INTERMACS Registry Data. ASAIO Journal, 2017, 63, 251-256.	0.9	20
42	Idiopathic Pulmonary Arterial Hypertension: Evolving Therapeutic Strategies. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 606-618.	0.8	5
43	Targeting heart failure with preserved ejection fraction: current status and future prospects. Vascular Health and Risk Management, 2016, 12, 129.	1.0	24
44	A Bayesian Model to Predict RightÂVentricular Failure Following LeftÂVentricular Assist Device Therapy. JACC: Heart Failure, 2016, 4, 711-721.	1.9	78
45	A New Bayesian Network-Based Risk Stratification Model for Prediction of Short-Term and Long-Term LVAD Mortality. ASAIO Journal, 2015, 61, 313-323.	0.9	43
46	Pulmonary hypertension in potential heart transplant recipients. Current Opinion in Organ Transplantation, 2015, 20, 570-576.	0.8	9
47	Successful Treatment of Acute Left Ventricular Assist Device Thrombosis and Cardiogenic Shock with Intraventricular Thrombolysis and a Tandem Heart. ASAIO Journal, 2015, 61, 98-101.	0.9	5
48	Management of Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction. Current Hypertension Reports, 2014, 16, 501.	1.5	5
49	Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension. Expert Review of Clinical Pharmacology, 2014, 7, 415-421.	1.3	3
50	New Drugs and Devices in the Pipeline for Heart Failure with Reduced Ejection Fraction Versus Heart Failure with Preserved Ejection Fraction. Current Heart Failure Reports, 2014, 11, 374-381.	1.3	7
51	Role of Phosphodiesterase-5 Inhibitors in Heart Failure: Emerging Data and Concepts. Current Heart Failure Reports, 2013, 10, 26-35.	1.3	15
52	Transitioning from Parenteral Treprostinil to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 116-120.	0.8	10
53	Time to Antibiotics for Community-Acquired Pneumonia. Infectious Diseases in Clinical Practice, 2012, 20, 58-62.	0.1	0
54	Chronic Thromboembolic Pulmonary Hypertension. Heart Failure Clinics, 2012, 8, 475-483.	1.0	6

#	Article	IF	CITATIONS
55	Heart connection of the mind medication. BMJ Case Reports, 2011, 2011, bcr1020103428-bcr1020103428.	0.2	1
56	Confusion About Epinephrine Dosing Leading to latrogenic Overdose: A Life-Threatening Problem With a Potential Solution. Annals of Emergency Medicine, 2010, 55, 341-344.	0.3	106
57	Fulminant Giant Cell Myocarditis and Cardiogenic Shock: An Unusual Presentation of Malignant Thymoma. Cardiology Research and Practice, 2010, 2010, 1-4.	0.5	12
58	Chronic Kidney Disease and Mortality in Implantable Cardioverter-Defibrillator Recipients. Cardiology Research and Practice, 2010, 2010, 1-6.	0.5	13
59	Postpartum ovarian vein thrombosis presenting as ureteral obstruction. BMJ Case Reports, 2010, 2010, bcr0320102863-bcr0320102863.	0.2	4
60	Traumatic Brachiocephalic Pseudoaneurysm Presenting as Stroke in a Seventeen-Year-Old. Clinical Cardiology, 2009, 32, E43-E45.	0.7	11
61	Misdiagnosis of Community-Acquired Pneumonia and Inappropriate Utilization of Antibiotics. Chest, 2007, 131, 1865-1869.	0.4	209